Navigation Links
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

, long-lasting stimulator of neutrophils and an efficient mobilizer of CD34+ stem cells. The drug exhibited a median half-life approximately 2.3 times that of Neulasta. No serious adverse events were reported, and there were no dose-limiting toxicities. No binding or neutralizing antibodies were found at any dose level, with dose levels ranging from 10 - 150 micrograms per kilogram.


'"/>




Page: 1 2

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. Spray on contraceptive clears Phase I trial
9. Phase 3 trials of two multi-kinase inhibitors against cancer
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Phase II trails of new HIV vaccine to be held in South Africa
Post Your Comments:
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
(Date:4/17/2014)... Researchers from LSTM have called for more research ... coinfection in children in sub-Saharan Africa. In a ... LSTM,s Professor Russell Stothard, working with colleagues in ... Western Reserve University, in Cleveland Ohio, University of ... previous research into the joint burden of HIV/AIDS ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... by the RECIST Working Group published in the European ... more refined categorization of tumor response or various aspects of ... database. They found that modeling target lesion tumor growth ... beyond that of the other components of progression. The RECIST ...
(Date:4/14/2014)... USA The International and American Associations for Dental ... Diseases and Their Dental, Oral, and Craniofacial Manifestations." The ... Burke, Alison M. Boyce, Michael Collins, Brian L. Foster, ... Martha J. Somerman and J. Timothy Wright is published ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... illness as college grads, study finds , , WEDNESDAY, May 6 ... the worst health, a new study finds. , Almost ... in less than very good health, and levels of health ... released Wednesday by the Robert Wood Johnson Foundation Commission to ...
... Lower Risk of Fractures WASHINGTON, May 6 Of ... families, one of the most important is health knowledge, ... the National Osteoporosis Foundation. A Gift from Mothers ... Osteoporosis Awareness and Prevention Month, which is attempting to ...
... May 6 Endo Pharmaceuticals (Nasdaq: ENDP ) ... America and Merrill Lynch 2009 Health Care Conference on Wednesday, ... Holveck, President and Chief Executive Officer of Endo, will review ... live and can be accessed from Endo,s website at ...
... May 6 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC ... Company"), a developer,and a leading distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... Net service revenues increased 77% to $69.2 million- Visiting ... million- Net income increased 118% to $5.6 million- Diluted ... more shares outstandingLOUISVILLE, Ky., May 6 Almost Family, ... provider of home health nursing services, announced today its ...
... catch high percentage of skin cancers at Women,s Dermatologic ... As champions of sun safety and skin health, ... (WDS) provided free skin cancer screenings and education ... SC recently. In a busy day of outreach, local ...
Cached Medicine News:Health News:Less Education May Mean Poorer Health 2Health News:Less Education May Mean Poorer Health 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 2Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 4Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:China Medicine Announces Conference Call to Discuss First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 3Health News:Almost Family Reports First Quarter 2009 Results 4Health News:Almost Family Reports First Quarter 2009 Results 5Health News:Almost Family Reports First Quarter 2009 Results 6Health News:Almost Family Reports First Quarter 2009 Results 7Health News:Almost Family Reports First Quarter 2009 Results 8Health News:Almost Family Reports First Quarter 2009 Results 9Health News:Almost Family Reports First Quarter 2009 Results 10Health News:Almost Family Reports First Quarter 2009 Results 11Health News:Almost Family Reports First Quarter 2009 Results 12Health News:Almost Family Reports First Quarter 2009 Results 13Health News:Almost Family Reports First Quarter 2009 Results 14Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... EAST HANOVER, N.J., June 1, 2011 Novartis Pharmaceuticals ... its current oncology products and investigational agents at the ... Oncology (ASCO). These data underscore the company,s commitment to ... cancer. "Through our commitment to R&D and ...
... Actavis, an international generic pharmaceutical company, today announced that ... Administration to market Donepezil Hydrochloride Tablets a generic equivalent of ... Tablets 5mg and 10mg had US total sales of approximately ... according to IMS Health.     About ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S. 2
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: